Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomised, double-blind, multicentre phase 3 trial
Osteoporosis International · 4 Nov 2026
† Impact is the editorial-priority score. All scores are out of 100. Clinical is how far this paper should move patient care if its methods hold up; it does not measure the size of a treatment benefit.
Why it matters
Denosumab biosimilars may lower cost and widen access to a key antiresorptive for osteoporosis, which matters for secondary fracture prevention after fragility fractures seen on orthopaedic services.
The evidence
This double-blind trial randomised 514 Chinese postmenopausal women (aged 60 to 90) with osteoporosis at high fracture risk to HLX14, a proposed denosumab biosimilar, or European reference denosumab, 60 mg every six months. At 52 weeks lumbar spine BMD rose 6.10% with HLX14 versus 5.90% with reference denosumab (adjusted difference 0.23%, 95% CI -0.48 to 0.95), inside the prespecified equivalence margin of plus or minus 1.45%; bone resorption marker suppression, fractures, adverse events and antibody rates were also similar, including after a single switch from reference drug to HLX14.
A coherent primary effect estimate is unavailable. Clinical relevance does not estimate treatment benefit.
Why this rigour score?
Multicentre RCTDesign starting point: 63.4
Raised the score
- Adequately powered+6
- Prospectively registered+5.1
Lowered the score
No negative adjustments recorded.
Methods at a glance
Recorded assessment- Outcome assessors blindedMet
- Allocation concealedNot reported
- Random sequence generatedMet
- Intention-to-treat analysisMet
- Adequate statistical powerMet
- Prospective registrationMet
Not reported does not mean not done. Checks have different weights; this is not a count of boxes ticked.
See the full score breakdown
- Study design starting point
- 63.4
- Random sequence generation
- +2.5
- Compared against current standard of care
- +3.4
- Blinded outcome assessment
- +3.4
- Intention-to-treat analysis
- +3.4
- 0% loss to follow-up
- +1.7
- Adequately powered
- +6
- Prospectively registered
- +5.1
- Final rigour score rounded
- 89 / 100
Study design sets the starting point and a ceiling of 100. Recorded methods then adjust the score. Points are shown to one decimal place; the final score uses unrounded values.
Checklist from the stored appraisal. “Not met” describes the recorded criterion; it does not always produce a deduction. This overview supports reading the full study.
How the clinical score was reached
The question: 7/9. Three judgements of how much it matters to patients, which decision it informs and how closely it fits their care.
Patient consequence: limited (1/3). A surrogate or intermediate outcome whose link to how patients feel or function is uncertain: radiographic or imaging findings, laboratory values, biomechanical or range-of-motion measures, healing on imaging, process or resource measures; or a trivial patient outcome.
Decision relevance: high (3/3). The study compares the actual options a clinician chooses between (or a whole strategy), and its primary result directly indicates which to choose, or that they are interchangeable. A clinician could act on it without a further translation step.
Applicability: moderate (3/3). A recognisable practice population, but with a notable restriction: narrow eligibility, a single expert surgeon or centre, or an unusual protocol that would need adapting. Applicability only subtracts for a real mismatch, so moderate counts in full.
What it found: Clear answer of no important difference (×0.94). No difference from a trial powered to find one, or from a review rating its certainty moderate or high, or a prespecified non-inferiority or equivalence margin met. No primary interval or verdict was extracted, so this answer is the appraisal's own judgement of the paper, held to the same power and certainty rules.
The design ceiling: 92. The most a multicentre rct can score here, however relevant its question and clear its answer.
Clinical = 92 × 7/9 × 0.94 = 67.
For journal club
1.If a cheaper denosumab biosimilar becomes available, how would you counsel an older woman after a fragility fracture about starting denosumab versus a bisphosphonate, given the need for indefinite dosing or a planned transition at discontinuation?
2.How should orthopaedic fracture liaison services monitor patients switched from reference denosumab to a biosimilar, and what would prompt concern about loss of effect?
Original publication title
Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial